1. Home
  2. GRI vs NCPL Comparison

GRI vs NCPL Comparison

Compare GRI & NCPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.31

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

NCPL

Netcapital Inc.

HOLD

Current Price

$0.40

Market Cap

3.6M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRI
NCPL
Founded
2018
1984
Country
United States
United States
Employees
N/A
20
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
3.6M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
GRI
NCPL
Price
$2.31
$0.40
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$160.00
N/A
AVG Volume (30 Days)
73.1K
153.7K
Earning Date
05-14-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$739.37
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.18
$0.31
52 Week High
$6.70
$8.75

Technical Indicators

Market Signals
Indicator
GRI
NCPL
Relative Strength Index (RSI) 46.40 44.95
Support Level $2.15 $0.37
Resistance Level $2.72 $0.47
Average True Range (ATR) 0.19 0.04
MACD -0.01 0.00
Stochastic Oscillator 37.12 35.30

Price Performance

Historical Comparison
GRI
NCPL

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About NCPL Netcapital Inc.

Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.

Share on Social Networks: